(0)Items in cart View Checkout

LiverRevive

Natural Prostate Care

$57.61


60 Tablets 1500 mg of Vitamin A

  • Protects the liver
  • Stimulates digestion
  • Increases bile flow
  • Treats digestive disturbances

 

• Protects the liver
• Stimulates digestion
• Increases bile flow
• Treats digestive disturbances
 

Hepatonic is one half of our specialized formulations designed to help with detoxification, to maintain liver health and support liver functions.  The main function of the liver is to filter the blood coming from the digestive tract before it is passed to the rest of the body. It is also responsible for detoxifying chemicals and secrete bile that will further breakdown food. Milk thistle (silymarin) is a flowering herb that is native to Mediterranean countries and is used as a natural treatment for liver problems such as cirrhosis, jaundice, hepatitis and gallbladder disorders. Other ingredients found in this formulation include N-Acetyl-L-Cysteine, picrorhiza, boldo, globe artichoke, dandelion, etc. These ingredients are also present to support healthy liver functions and health but they also help stimulate digestion, increase bile flow and flushing of the urinary tract. For a more complete liver care and detoxification, it is recommended to take with LiverCalm.

 

Why Herbalgenn?


The application of Structurally Active-Orthogenic (SAO) technology by Herbalgenn’s research and production team ensures that all available products are of a heightened quality. 

SAO technology produces active ingredients with strong molecular composition and the highest bioavailability (ratio of inactive/active ingredients) in order to ensure synergistic applications occur within the body. In other words, the Herbalgenn label ensures that all our products are able to be optimally absorbed by the bloodstream at the molecular level, and don’t just pass through the body undigested. 

Herbalgenn is pharmaceutically tested and clinically verified by careful examination at every stage of production. The protocols are measured and confirmed for international standard compliance before the product is introduced to market. 

Herbalgenn only uses 100% natural ingredients. 




Active Ingredients

N-Acetyl-L-Cysteine (100 mg), Silybum Marianum (100 mg), Peumus Boldus (25 mg), Cynara cardunculus (25 mg), Taraxacum Officinale (25 mg), Picrorhiza Kurrooa (7 mg), Vitamin B6 (5 mg), Folic Acid (50 mcg), Vitamin B12 (50 mcg).

ALSO CONTAINS

Dicalcium phosphate magnesium stearate, stearic acid, microcrystalline cellulose, silicon dioxide, croscarmellose sodium.

Does not contain gelatin, gluten, artificial colours, preservatives or GMOs.

HepaTonic

 

NPN:

80085955

Quantity:

60 Tablets

Recommended Dose:

Adults: Take 2 tablets once daily with a meal.

Cautions:

Consult a physician prior to use if you have kidney stones, impaired kidney or liver function, gallstones, liver or gall bladder diseases or an intestinal obstruction. Consult a physician if symptoms persist or worsen. Do not use this product if you are taking antibiotics, nitroglycerin, if you are pregnant or breastfeeding, if you are allergic to plants of the Asteraceae, Compositae or Daisy family or if you have a bile duct obstruction. Hypersensibility may occur, in which case, discontinue use. Laxative effect may occur. Keep out of reach of children.





Background


Biogenique Prostate Protect is formulated with traditional herb Saw palmetto, prunus africana, berries extract and pumpkin seeds. Saw palmetto (Serenoa repens/Sabal serrulata) is a palm like plant with berries that were a staple food and medicine for the Native Americans of the southeastern United States. Saw palmetto is used popularly in Europe for symptoms associated with benign prostatic hyperplasia (enlargement of the prostate), it is the most popular herbal treatment for this condition.

Biogenique Structurally Active-Orthogenic (SAO) technology


Our researchers found that Saw palmetto used in combination with berries extract and pumpkin seeds are particularly beneficial for prostate gland. The combination of these plant-based chemicals may be effective for treating benign prostatic hyperplasia (BPH). 

Saw palmetto contains active ingredients like fatty acids, plant sterols, and flavonoids, the berries contain high molecular weight polysaccharides (sugars) while pumpkin seeds are rich in zinc content which are found to be important for prostate health. 

Biogenique SAO technology designs formula by combining the medicinal properties of all these herbs in balanced proportion. It preserves the nutrient content within active ingredients intact without destroying their medicinal properties. 

SAO technology establishes a higher caliber of science for better quality research and formulation. It makes sure that the compounds are delivered on their potential to create effectiveness. 

SAO Analysis


Saw palmetto:
Historical use of saw palmetto can be traced in the Americas to the Mayans who used it as a tonic and to the Seminoles who took the berries as an expectorant and antiseptic. Researchers think that SAO designed saw palmetto appears to possess 5-α-reductase inhibitory activity (thereby preventing the conversion of testosterone to dihydrotestosterone) on androgen receptors. This hormonal/estrogenic effects as well as anti-inflammatory properties may affect the level of testosterone in the body, and perhaps reduce the amount of an enzyme that promotes the growth of prostate cells responsible for prostate enlargement. 

Pumpkin seeds:
Pumpkin seeds have long been valued as an important natural food for men’s health. This is in part because of their high zinc content, which is important for immunity, cell growth, sleep, mood, senses of taste and smell, eye and skin health, insulin regulation, prostate health and male sexual function. In body, zinc is found in highest concentration in prostate gland. 

Scientific Evidence


Enlarged prostate (benign prostatic hyperplasia/BPH)

Numerous human trials report that saw palmetto improves symptoms of benign prostatic hyperplasia (BPH) such as nighttime urination, too frequent urination, having trouble starting or maintaining urination and overall quality of life, although it may not greatly reduce the size of the prostate. The urethra, the tube that empties urine from the body, runs through the prostate gland in men; when the prostate gland is enlarged, men may have trouble urinating. Some studies show that, the effectiveness may be similar to the medication finasteride (Proscar®) with fewer side effects, such as loss of libido. Other studies suggest that saw palmetto may actually shrink the size of the prostate gland. Due to the short duration (usually less than 3 months) of these studies, it is not possible to say for sure whether saw palmetto is truly effective for preventing complications of BPH. It is important to receive a proper diagnosis of BPH from your health care provider to rule out prostate cancer. 

Male-pattern hair loss

It has been suggested that saw palmetto may block some effects of testosterone and therefore reduce male pattern hair loss, similar to the medication finasteride (Propecia®). More studies are necessary before saw palmetto can be recommended for this use. 

Preparation for surgery

(Transurethral resection of prostate) Saw palmetto may help the recovery process in patients undergoing prostate surgery. Saw palmetto may reduce bleeding after surgery and also reduce catheter use. More study is needed in this area. 

Prostate cancer

Animal studies show that saw palmetto inhibits the growth of tumor cells, indicating that it may be helpful in the treatment of prostate cancer. While these studies are promising, more research is needed to determine whether saw palmetto is effective for these conditions. There is not enough scientific evidence to recommend the product which contains saw palmetto for prostate cancer. 

Prostatitis/chronic pelvic pain syndrome (CP/CPPS)

A prospective, randomized, open label, one-year study was designed to assess the safety and efficacy of saw palmetto and finasteride in the treatment of men diagnosed with category III prostatitis/chronic pelvic pain (CP/CPPS). CP/CPPS treated with saw palmetto had little but not appreciable long-term improvement. In contrast, patients treated with finasteride had significant and durable improvement in multiple parameters except for voiding. 

Safety


• The use of herbs is a time honored approach to strengthening the body and treating disease. Herbs, however, can trigger side effects and interact with other herbs, supplements, or medications. For these reasons, you should take herbs with care, under the supervision of a health care provider.

• Saw palmetto is generally thought to be safe when used as directed. Side effects are very rare, although mild stomach complaints and minor headaches may occur.

• Do not self-treat for BPH with saw palmetto; see your health care provider for a proper diagnosis to rule out prostate cancer.

• Saw palmetto may interfere with the absorption of iron. 

Interactions you should know about


• Finasteride(Proscar) -- Because saw palmetto may work similarly to finasteride (Proscar), you should not use this herb in combination with finasteride or other medications used to treat BPH unless directed to by your physician.

• Antiplatelet and anticoagulant drugs (blood-thinners) -- Saw palmetto may affect the blood's ability to clot, and could interfere with blood-thinning drugs, including: Warfarin (Coumadin), Clopidogrel (Plavix) and Aspirin 

Selected references


1. Avins AL, Bent S. Saw palmetto and lower urinary tract symptoms: what is the latest evidence? Curr Urol Rep 2006 Jul;7(4):260-5.

2. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl.J Med 2-9-2006;354(6):557-566.

3. Boyle P., Robertson C., Lowe F., et al. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55(4):533-539.

4. Braeckman J, Denis L, de Leval J, et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997;9:247-259.

5. Edwards JL. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician. 2008 May 15;77(10):1403-10.

6. Engelmann U, Walther C, Bondarenko B, et al. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittelforschung. 2006;56(3):222-9.

7. Feifer AH, Fleshner NE, et al. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J.Urol 2002;168(1):150-154.

8. Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51(6):1003-1007.

9. Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58(6):960-964.

10. Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004;171(1):284-288.

11. Magri V, Trinchieri A, Pozzi G, et al. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. Int J Antimicrob Agents 2007 May;29(5):549-56.

12. Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol.Nephrol 2001;33(2):217-225. 




I)Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study.


Source

Department of Urology and Department of Hygiene and Public Health, University of Catania, Catania, Italy. 

ABSTRACT

OBJECTIVE: 

To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI). 

MATERIALS AND METHODS: 

We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + a-blockers treatment (group II) for 3 months or to control group (group IIc). After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68). 

RESULTS: 

At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. 

CONCLUSION: 

Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients. 

II)Comparative evaluation of the efficiency of prostatotropic agents of natural origin in experimental benign prostatic hyperplasia.


Source

Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. repropharm@yandex.ru 

ABSTRACT

Comparative evaluation of the efficiency of prostatotropic agents was carried out in rat experiments. Serenoa repens plant preparation and polypeptides isolated from the cattle prostate were used for the treatment of benign hyperplasia. Drugs in parallel with sulpiride similarly led to shrinkage of the acinar epithelial area and to emergence of a trend to an increase of the stromal/epithelial proportion, more so after Serenoa repens treatment. 

III)Effect of Serenoa repens (Permixon(R)) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma.


ABSTRACT

BACKGROUND: 

To analyze the expression at basal level of inflammation-related cytokines and chemokines and the activation status of the NF-kappaB pathway, together with the proliferation and apoptosis indexes in two widely used in vitro tumor models, the androgen-dependent human Prostate Cancer (PC) cell line LNCaP and the androgen-independent PC3 , and in primary cultures of human PC cells. To assess in these models and primary cultures, the effects of Serenoa repens (LSESr, Permixon(R)) on proliferation/apoptosis ratio, inflammation-related genes expression and NF-kappaB pathway activation. 

METHODS: 

The expression of IL-6, CCL-5, CCL-2, COX-1, COX-2, iNOS inflammation-related genes has been evaluated at the mRNA level in two in vitro human PC models (LNCaP and PC3 cell lines) and in 40 independent human prostatic primary cultures obtained from PC patients undergoing radical prostatectomy. Tissue fragments were collected from both PC lesions and normal hyperplastic tissue counterparts for each case. All cultures were treated with two different amounts of Permixon(R) (44 and 88 mug/ml) for different time points (16, 24, 48 and 72 hours), depending on the cell type and the assay; the expression of inflammation-related genes, cell growth (proliferation/apoptosis ratio) and NF-kappaB activation has been analyzed in treated and untreated cells by means of semi-quantitative RNA-PCR, cell proliferation and immunofluorescence respectively. 

RESULTS: 

We detected a significant reduction (p <0.001) in PC and normal cells proliferation due to Permixon (R) treatment. This result was related to an increase of the apoptotic activity showed by an increase in the number of anti-caspase-3 fluorescent cells. Almost all the inflammation-related genes (IL-6, CCL-5, CCL-2, COX-2 and iNOS) were expressed at the basal level in in vitro cultured cells and primary cultures and down-regulated by Permixon(R) treatment. This treatment interfered with NF-kB activation, detecting by the translocation of more than 30% of NF-kappaB p65 subunit to the nucleus. 

CONCLUSION: 

The present study confirms the expression of inflammatory pattern in PC. We showed the effect of Permixon(R) on down-regulation of inflammatory-related genes in cell lines and in primary cultures. The inhibitory effect of Permixon(R) on cell growth could be partly associated to the down-regulation of inflammatory-related genes and to the activation of NF-kappaB pathway in prostate tissue. 

IV) Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation.


Source

Villa Tiberia Clinic, Urology Department, Rome, Italy. roberto.giulianelli@virgilio.it 

ABSTRACT

INTRODUCTION: 

Chronic benign prostate diseases are very common and certainly feature significantly in urological practice.The treatment of chronic benign prostate diseases is a common problem in clinical practice: few studies have been conducted in routine clinical practice to evaluate the efficacy of the treatments for this clinical condition. The objective of this study was to evaluate the efficacy of an extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms (LUTS) in patients with chronic benign prostate diseases with associated inflammation, also taking into consideration the influence of treatment on sexual function and, therefore, on patients' quality of life. 

MATERIALS AND METHODS: 

All the 591 eligible subjects were evaluated on entering the study; after a screening visit, including medical history, physical examination, physical examination and digital rectal examination (DRE) and laboratory tests, the patients underwent uroflowmetry. The subjects under investigation were also asked to complete the IPSS, NIH-CPSI and IIEF-5 questionnaires, for the purpose of evaluating urinary symptoms and erectile function in relation to sexual activity in the previous 6 months. 

RESULTS: 

The analysis of the uroflowmetry results showed that treatment with extract of Serenoa repens distinctly improves bladder voiding and lower urinary tract symptoms, as highlighted also by the improvement in the scores for the IPSS and NIH-CPSI questionnaires which serve as a basis for evaluating the urinary symptoms of patients with prostatic hyperplasia and chronic prostatitis respectively. The results also suggest that using an extract of Serenoa repens for 6 months in patients with chronic benign prostate diseases gives rise to an improvement in erectile function, as demonstrated by the increase in the scores for the IIEF-5 questionnaire after 6 months of treatment. 

CONCLUSION: 

The results of this study demonstrate how treatment for 6 months with an extract of Serenoa repens in routine clinical practice gives rise to a statistically significant improvement in Qmax values and in the IPSS, NHI-CPSI and IIEF-5 questionnaire scores, resulting not only in an improvement in urinary symptoms but also in an overall improvement in patients' quality of life. 






Customers who bought this item also bought: